News
-
-
COMMUNIQUÉ DE PRESSE
As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo
NanoViricides announces National Ethics Committee approval for Phase II Clinical Trial of NV-387 Oral Gummies as Treatment for Bundibugyo Ebola; focusing on broad-spectrum antiviral treatment for pandemics -
-
-
COMMUNIQUÉ DE PRESSE
Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily
NanoViricides, Inc. reports a new research report with 'Outperform' rating and target price of $6.00. Interview with President on antiviral drugs and future plans -
-
-
COMMUNIQUÉ DE PRESSE
As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo
NanoViricides, Inc. updates advancement of NV-387 broad-spectrum antiviral drug towards Phase II Clinical Trial for Bundibugyo Ebolavirus treatment in the DRC amid expanding outbreak. An oral gummies formulation has potential against Ebola viruses -
-
